Robin Swartz Biography and Net Worth

Chief Business Officer and Chief Operating Officer of Voyager Therapeutics

Ms. Swartz has served as our Chief Operating Officer and Business Officer since November 2024, and previously served as our Chief Operating Officer from February 2022 to November 2024, our Principal Financial Officer and Principal Accounting Officer from April 2024 to July 2024, our Senior Vice President, Business Operations from September 2021 to February 2022 and our Senior Vice President, Portfolio Management and Patient Engagement from January 2021 to August 2021. Prior to joining us, Ms. Swartz served in positions of increasing responsibility beginning in 1995 at Genzyme Corporation and Sanofi Genzyme, culminating in her service at Sanofi Genzyme as Senior Vice President, Patient and Product Services for Rare Diseases from January 2018 to June 2020 and as Senior Vice President, Head of Global and US Business Operations from June 2015 to December 2017. Her previous roles at Sanofi Genzyme included Chief of Staff to the Executive Vice President, Head of Sanofi Genzyme and Senior Director, Finance. Ms. Swartz spent over ten years serving in roles of increasing responsibility in the Finance department at Sanofi Genzyme, with a focus on finance operations, internal auditing, and financial planning and analysis. Ms. Swartz received a B.A. in political science and government from Kenyon College.

What is Robin Swartz's net worth?: The estimated net worth of Robin Swartz is at least $620.19 thousand as of February 24th, 2026. Ms. Swartz owns 199,738 shares of Voyager Therapeutics stock worth more than $620,186 as of July 22nd. This net worth evaluation does not reflect any other assets that Ms. Swartz may own. Learn More about Robin Swartz's net worth.
How do I contact Robin Swartz?: The corporate mailing address for Ms. Swartz and other Voyager Therapeutics executives is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. Voyager Therapeutics can also be reached via phone at (857) 259-5340 and via email at [email protected]. Learn More on Robin Swartz's contact information.
Has Robin Swartz been buying or selling shares of Voyager Therapeutics?: Robin Swartz has not been actively trading shares of Voyager Therapeutics during the last quarter. Most recently, Robin Swartz sold 6,458 shares of the business's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $3.77, for a transaction totalling $24,346.66. Following the completion of the sale, the chief operating officer now directly owns 199,738 shares of the company's stock, valued at $753,012.26. Learn More on Robin Swartz's trading history.
Who are Voyager Therapeutics' active insiders?: Voyager Therapeutics' insider roster includes Julie Burek (VP), Todd Carter (Chief Scientific Officer), Alfred Sandrock (President and Chief Executive Officer), and Robin Swartz (Chief Business Officer and Chief Operating Officer). Learn More on Voyager Therapeutics' active insiders.
Are insiders buying or selling shares of Voyager Therapeutics?: In the last year, insiders at the sold shares 9 times. They sold a total of 68,960 shares worth more than $269,884.60. The most recent insider tranaction occured on April, 2nd when CEO Alfred Sandrock sold 11,511 shares worth more than $44,547.57. Insiders at Voyager Therapeutics own 12.7% of the company. Learn More about insider trades at Voyager Therapeutics.
Information on this page was last updated on 4/2/2026.

Robin Swartz Insider Trading History at Voyager Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/24/2026	Sell	6,458	$3.77	$24,346.66	199,738
2/10/2026	Sell	4,569	$3.85	$17,590.65	210,078
1/14/2025	Sell	3,087	$5.09	$15,712.83	109,241
12/23/2024	Sell	6,500	$5.65	$36,725.00	112,328
1/17/2024	Sell	2,543	$7.15	$18,182.45	72,327
4/3/2023	Sell	1,259	$7.83	$9,857.97	71,617
3/20/2023	Sell	3,654	$7.76	$28,355.04	72,876
4/4/2022	Sell	1,527	$8.25	$12,597.75	52,060
3/21/2022	Sell	4,413	$8.29	$36,583.77

Robin Swartz Buying and Selling Activity at Voyager Therapeutics

Voyager Therapeutics Company Overview

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $3.11

$3.06

$3.12

50 Day Range

MA: $3.59

$3.04

$4.24

2 Week Range

Now: $3.11

$2.88

$5.55

Volume

241,774 shs

Average Volume

657,959 shs

Market Capitalization

$187.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27